Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

Vertex had plans to hire 1,300 employees in Wilmington, but it never even got close.

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from ...

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...

Vertex Solutions Earns Contract to Provide Immersive Training to Air Force Branch to receive delivery of 25 advanced tech T-38 Gen 2 training devices.

Google just made it ridiculously easy to create a video from text prompts, thanks to the newly announced Vertex AI Studio.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment.